Filing Flows › Caribou Biosciences (CRBU) › Q2 2026
Caribou Biosciences (CRBU) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Caribou Biosciences (CRBU) reported revenue of $1.5M for the second quarter 2026 (Q2 2026), -44% from a year earlier and -37% from the quarter before.
Caribou Biosciences, Q2 2026: revenue $1.5M (-44% year over year), net loss $24.3M, operating cash flow −$22.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -37% | -44% |
| Operating profit | −$25.3M | — | — |
| Net earnings | −$24.3M | — | — |
| Operating cash flow | −$22.8M | — | — |
What changed
Revenue was $1.5M in Q2 2026, down 44% year over year and down 37% from the previous quarter.
Operating costs exceeded revenue by $25.3M, an operating margin of -1690.4%. Total costs fell 47% while revenue fell 44%. The quarter ended with a net loss of $24.3M, narrower than the previous quarter's $25.1M loss.
Operating cash flow was −$22.8M. Non-cash charges added back $625K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $1.6M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$22.8M.
Questions
What was Caribou Biosciences' revenue in the second quarter 2026?
Caribou Biosciences (CRBU) reported revenue of $1.5M for the second quarter 2026 (Q2 2026), -44% from a year earlier and -37% from the quarter before.